Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomson, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomson, C. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. A, 31-40
© 1999 The British Society for Antimicrobial Chemotherapy

The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective

Christopher J. Thomson*

Pharmaceutical Division, Bayer plc, Bayer House, Strawberry Hill, Newbury, Berkshire, UK

Many studies have examined the in-vitro activity of ciprofloxacin. The results are for the most part encouraging but we must guard against complacency. Levels of ciprofloxacin resistance vary geographically, while some predictably difficult-to-treat organisms such as Pseudomonas aeruginosa,Staphylococcus aureus and Acinetobacter baumannii present challenges globally. The emergence of resistance in species previously exquisitely sensitive to ciprofloxacin, such as Neisseria gonorrhoeae, in countries associated with `pirate' production and indiscriminate use of antimicrobials represents a major challenge. Ciprofloxacin continues to show excellent activity againstHaemophilus influenzae and Moraxella catharralis. In general, ciprofloxacin shows good activity against Enterobacteriaceae although the emergence of reduced susceptibility and, sometimes, quinolone resistance in multi-resistant isolates should be noted.

* Tel: +44-(0)1635-563-406; Fax: +44-(0)1635-563-419; E-mail: chris.thomson.ct{at}bayer.co.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
D. Baldoni, M. Haschke, Z. Rajacic, W. Zimmerli, and A. Trampuz
Linezolid Alone or Combined with Rifampin against Methicillin-Resistant Staphylococcus aureus in Experimental Foreign-Body Infection
Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1142 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 Journal of the American Animal Hospital AssociationHome page
B. E. Wildermuth, C. E. Griffin, W. S. Rosenkrantz, and M. J. Boord
Susceptibility of Pseudomonas Isolates From the Ears and Skin of Dogs to Enrofloxacin, Marbofloxacin, and Ciprofloxacin
J. Am. Anim. Hosp. Assoc., November 1, 2007; 43(6): 337 - 341.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. L. LaPlante, M. J. Rybak, B. Tsuji, T. P. Lodise, and G. W. Kaatz
Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin
Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1315 - 1320.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Gao, M. E. Pennesi, X. Qiao, M. N. Iyer, S. M. Wu, E. R. Holz, and W. F. Mieler
Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models.
Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1606 - 1611.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. J. Harnett, A. P. Fraise, J. M. Andrews, G. Jevons, N. P. Brenwald, and R. Wise
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492
J. Antimicrob. Chemother., May 1, 2004; 53(5): 783 - 792.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. W. Kaatz, V. V. Moudgal, and S. M. Seo
Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus
J. Antimicrob. Chemother., December 1, 2002; 50(6): 833 - 838.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. Fuursted and H. Schumacher
Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model
J. Antimicrob. Chemother., September 1, 2002; 50(3): 421 - 424.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Marie, H. Morvan, F. Berthelot-Herault, P. Sanders, I. Kempf, A. V. Gautier-Bouchardon, E. Jouy, and M. Kobisch
Antimicrobial susceptibility of Streptococcus suis isolated from swine in France and from humans in different countries between 1996 and 2000
J. Antimicrob. Chemother., August 1, 2002; 50(2): 201 - 209.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. E. Peacock Jr., D. A. Herrington, J. C. Wade, H. M. Lazarus, M. D. Reed, J. W. Sinclair, D. C. Haverstock, S. F. Kowalsky, D. D. Hurd, D. A. Cushing, et al.
Ciprofloxacin plus Piperacillin Compared with Tobramycin plus Piperacillin as Empirical Therapy in Febrile Neutropenic Patients: A Randomized, Double-Blind Trial
Ann Intern Med, July 16, 2002; 137(2): 77 - 87.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.